Lessons from the ASPIRE trial: three drug regimens as the new SOC for relapsed MM
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
Gareth Morgan et al.
Which is the best combination therapy in relapsed and refractory multiple myeloma?
Comparing continuous and fixed duration myeloma treatment with triplets and doublets